The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Hospira, Inc., a Pfizer company, is recalling the below-referenced lots of ABBOJECT® products; 4.2% Sodium Bicarbonate Injection, USP, 1% and 2% Lidocaine HCl Injection, USP due to the possibility of glass particulates in the products. Pfizer completed a Health Hazard Assessment which concluded that the use of the impacted product has an unlikely probability of occurrence of adverse effects such as myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, and thrombophlebitis or mild pain. The potential risk to the patient arising from this issue is considered to be low.

To date, Pfizer has not received reports of any adverse events associated with this issue for these lots.

## 4.2% Sodium Bicarbonate Injection, USP

| Product                  | NDC              | Lot    | Expiration | Strength     | Configuration/Count     |
|--------------------------|------------------|--------|------------|--------------|-------------------------|
|                          |                  | Number | Date       |              |                         |
| 4.2% Sodium              | Carton           | GJ5007 | 1AUG2024   | 5 mEq/10mL   | 1 vial and injector per |
| Bicarbonate              | 0409-5534-<br>24 |        |            | (0.5 mEq/mL) | carton;                 |
| Injection, USP           | Case             |        |            |              | 10 cartons per bundle;  |
| Glass ABBOJECT®  Syringe | 0409-5534-<br>14 |        |            |              | Case Pack 5 X 10 – 10mL |

## 1% Lidocaine HCl Injection, USP

| Product             | NDC    | Lot     | Expiration Strength Configuration/Co |            |                         |
|---------------------|--------|---------|--------------------------------------|------------|-------------------------|
|                     |        | Number  | Date                                 | 8          | 8                       |
| 1% Lidocaine<br>HCl | Carton | 42290DK | 1JUN2024                             | 50 mg /5mL | 1 vial and injector per |

| Injection, USP     | 0409-4904-<br>11 | (10 mg/mL) | carton;                |
|--------------------|------------------|------------|------------------------|
| LIFESHIELD®        | Case             |            | 10 cartons per bundle; |
| Glass<br>ABBOJECT® | 0409-4904-<br>34 |            | Case Pack 5 X 10 – 5mL |
| Syringe            |                  |            |                        |

## 2% Lidocaine HCl Injection, USP

| Product                 | NDC              | Lot    | Expiration | Strength   | Configuration/Count     |
|-------------------------|------------------|--------|------------|------------|-------------------------|
|                         |                  | Number | Date       |            |                         |
| 2% Lidocaine<br>HCl     | Carton           | GH6567 | 1JUL2024   | 100 mg/5mL | 1 vial and injector per |
| Injection, USP          | 0409-4903-<br>11 |        |            | (20 mg/mL) | carton;                 |
| LIFESHIELD®             | Case             |        |            |            | 10 cartons per bundle;  |
| Glass ABBOJECT® Syringe | 0409-4903-<br>34 |        |            |            | Case Pack 5 X 10 – 5mL  |